Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Expanded Taxus recall

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific recalls roughly 85,000 paclitaxel-eluting stent systems and 11,000 Express2 bare-metal stent systems, citing balloon-deflation defects in some related delivery catheters. The company reports one death and 18 serious injuries associated with Taxus, and two deaths and 25 serious injuries linked to Express2 implants. In a Class I recall July 1, the firm withdrew 200 units but subsequently determined that many more Taxus and Express2 products - manufactured at Boston Scientific's Galway, Ireland and Maple Grove, Minn. facilities - also may have faulty balloon catheters (1"The Gray Sheet" July 5, 2004, p. 24). The expanded recall will cost $45 mil. in reversed sales in Q2, plus $50 mil. in written-down inventory, the firm gauges in a July 16 release...

You may also be interested in...

Boston Scientific Applies Lessons From Taxus Recall To Ireland Plant

Stent delivery catheter flaws that provoked a 96,000-unit recall will be prevented by newly installed laser control software at Boston Scientific's Galway, Ireland facility, according to the firm

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts